(Press-News.org) A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.
The Phase III AMPLITUDE trial, published in Nature Medicine, tested the addition of niraparib, a type of targeted cancer drug known as a PARP inhibitor1, to the standard treatment of abiraterone acetate and prednisone (AAP).2
The study focused on patients diagnosed with advanced prostate cancer where cells have spread to other parts of the body, who were starting their first treatment and who also had alterations in genes involved in an essential type of DNA defect repair, known as homologous recombination repair (HRR).
These genes help repair damaged DNA and when they are faulty, cancer cells can grow and spread more aggressively. Approximately one in four people with advanced prostate cancer at this stage have alterations in HRR genes, such as BRCA1, BRCA2, CHEK2, and PALB2.
The standard treatment for advanced prostate cancer is currently AAP (or similar drugs, with docetaxel chemotherapy offered to approximately one-in-five patients) but these mutations make the cancer more aggressive and consequently disease progression on standard treatment is often far quicker with shorter life expectancies.
Led by Professor Gerhardt Attard from UCL Cancer Institute, the trial enrolled 696 men across 32 countries with a median age of 68. Half received the new combination therapy (niraparib plus APP), while the other half received standard treatment with a placebo. Of all the patients, more than half (55.6%) had alterations in the BRCA1 or BRCA2 genes.
The trial was double-blind, meaning neither patients nor doctors knew which treatment was being administered.
Key findings
At a median follow-up of just over two and a half years (30.8 months), the researchers found that:
Overall, niraparib reduced the risk of cancer growth by 37% compared to AAP alone in all patients and by 48% in the subgroup of patients with BRCA1 or BRCA2 mutations.
The time until symptoms got worse was twice as long for patients who received niraparib compared to those who received a placebo, reducing the number of patients who had notable worsening in symptoms from 34% to 16%.
Researchers observed a trend toward improved overall survival in the niraparib group. However, a longer follow-up is needed to confirm that starting niraparib for this population of patients improves life expectancy.
Professor Attard said: "Although current standard treatments are very effective for the majority of patients with advanced prostate cancer, a small but very significant proportion of patients have limited benefit. We now know that prostate cancers with alterations in HRR genes account for a significant group of patients whose disease recurs quickly and has an aggressive course. By combining with niraparib we can delay the cancer returning and hopefully significantly prolonging life expectancy.
“These findings are striking because they support widespread genomic testing at diagnosis with use of a targeted treatment for patients who stand to derive the greatest benefit.
“For cancers with a mutation in one of the eligible HRR genes, where niraparib has been approved, a doctor should consider a discussion that balances the risks of side effects against the clear benefit to delaying disease growth and worsening symptoms.” 3
Side effects
While the treatment was generally well tolerated, side effects were more common in the niraparib group. Significantly more cases of anaemia and high blood pressure were reported with niraparib, and 25% of patients required blood transfusions. Treatment-related deaths were also higher in the niraparib group (14 versus 7), though overall discontinuation rates remained low.
The study’s authors note that while the results are promising, further research is needed to confirm long-term survival benefits and to explore the impact of newer imaging techniques and broader genetic testing.
Prostate cancer in numbers
Globally, an estimated 1.5 million men are diagnosed with prostate cancer each year. In the UK prostate cancer is the most common cancer in men, with more than 56,000 men diagnosed every year, and around 12,000 men die from the disease each year.
The AMPLITUDE trial was sponsored by Janssen Research & Development, part of Johnson & Johnson.
Notes to Editors
For more information contact:
Dr Matt Midgley
m.midgley@ucl.ac.uk
1PARP inhibitors, such as niraparib, are a type of targeted therapy that work by blocking the PARP protein, which is involved in repairing damaged DNA in cancer cells. By inhibiting PARP, the cancer cells are unable to repair the DNA damage, leading to their death.
2 Abiraterone acetate and prednisone (APP) are both hormone therapies. This combination blocks androgen production in the testes, adrenal glands, and the tumor itself, slowing cancer growth by reducing the available testosterone for the cancer cells.
3 In the UK, Niraparib is approved to treat some types of cancer but has not yet been approved for prostate cancer. The National Institute for Clinical Excellence has said it waiting for further information, before it can make a decision. https://www.nice.org.uk/guidance/ta1032
Publication
Gerhardt Attard et al. ‘Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial’ by will be published in Nature Medicine and is strictly embargoed until Tuesday 7 October 2025 at 10:00 BST / 05:00 ET.
DOI: https://doi.org/10.1038/s41591-025-03961-8
About UCL – London’s Global University
UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.
Since 1826, we have championed independent thought by attracting and nurturing the world's best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.
The Times and Sunday Times University of the Year 2024, we are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.
We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.
For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.
We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.
www.ucl.ac.uk | Follow @uclnews on Bluesky | Read news at www.ucl.ac.uk/news
END
New drug combination offers hope for men with advanced prostate cancer
2025-10-07
ELSE PRESS RELEASES FROM THIS DATE:
New discovery finds gene converts insulin-producing cells into blood-sugar boosters
2025-10-07
LOS ANGELES — Scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and a leading research center for diabetes and other life-threatening illnesses, have uncovered a gene called SMOC1 that plays a surprising role in the development of type 2 diabetes (T2D) by converting pancreatic cells that normally produce insulin into those that increase blood sugar.
The findings, published in Nature Communications, identify an important new therapeutic target for T2D and ...
Powerful and precise multi-color lasers now fit on a single chip
2025-10-07
A few years ago, researchers in Michal Lipson’s lab noticed something remarkable.
They were working on a project to improve LiDAR, a technology that uses lightwaves to measure distance. The lab was designing high-power chips that could produce brighter beams of light.
“As we sent more and more power through the chip, we noticed that it was creating what we call a frequency comb,” says Andres Gil-Molina, a former postdoctoral researcher in Lipson’s lab.
A frequency comb is a special type of light that contains many colors lined up next to each other in an orderly pattern, kind of like ...
Scientists agree chemicals can affect behavior, but industry workers more reluctant about safety testing
2025-10-07
Survey of 166 international experts highlights concerns about protecting human and wildlife health from environmental pollutants
Less than a third of industry scientists support including behavioural tests in chemical safety assessments, compared to 80 per cent of academics and 91 per cent of government scientists
Despite almost all scientists (97 per cent) agreeing that chemicals can affect wildlife behaviour, most testing is done by universities rather than chemical companies, leaving gaps ...
DNA nanospring measures cellular motor power
2025-10-07
Cells all require the transport of materials to maintain their function. In nerve cells, a tiny motor made of protein called KIF1A is responsible for that. Mutations in this protein can lead to neurological disorders, including difficulties in walking, intellectual impairment and nerve degradation. It’s known that mutations in KIF1A also result in a weakened motor performance, but this has been difficult to measure so far. Researchers including those from the University of Tokyo and the National Institute of Information and Communications Technology (NICT) in Japan have measured changes in the force of KIF1A using a nanospring, a tiny, coiled structure, ...
Elsevier Foundation and RIKEN launch “Envisioning Futures” report: paving the way for gender equity and women’s leadership in Japanese research
2025-10-07
A unique collaboration, the Elsevier Foundation and RIKEN, Japan’s premier research institute, have released “Envisioning Futures: Women’s Leadership and Gender Equity in Japanese Research,” a comprehensive report that shines a spotlight on the journeys, achievements and challenges faced by women research leaders in Japan. The report blends data-driven analysis with compelling personal narratives, offering a timely roadmap for institutional change and a call to action for the advancement of women in science and innovation.
The report shows that despite Japan’s global reputation for technological ...
Researchers discover enlarged areas of the spinal cord in fish, previously found only in four-limbed vertebrates
2025-10-07
Four-limbed vertebrates, known as tetrapods, have two enlarged areas in their spinal cords. The two enlargements have a correlation with the forelimbs and hind limbs, respectively. These enlargements are thought to be caused by the complex muscular system and the rich sensory networks supplying nerves to the limbs.
Meanwhile, it was long thought that fish had no enlarged areas in their spinal cords due to the absence of limbs. However, a recent study by scientists from Nagoya University in Japan has revealed that zebrafish, in fact, have enlarged areas in their spinal cords, although these areas are not visible ...
Bipolar disorder heterogeneity decoded: transforming global psychiatric treatment approaches
2025-10-07
HALIFAX, Nova Scotia, CANADA, 7 October 2025 -- In a compelling Genomic Press Interview published today in Genomic Psychiatry, Dr. Martin Alda illuminates how decoding psychiatric heterogeneity holds the key to revolutionizing mental health treatment worldwide. The interview reveals how this internationally acclaimed researcher transformed our global understanding of bipolar disorder by proving that what appears as one condition actually represents multiple genetically distinct disorders, fundamentally ...
Catching Alport syndrome through universal age-3 urine screening
2025-10-07
The most common first diagnosis of Alport syndrome in Japan is during the universal age-3 urine screening. In 60% of these children, the disease had already progressed far enough to qualify for treatment. Therefore, universal early-age urinalysis may be an apt means for both better prognoses and reduced costs of medical care.
Alport syndrome is a genetic disease that affects about one in 5,000 people. Patients cannot produce a certain type of collagen which leads to kidney failure, and may also lead to hearing loss and ...
Instructions help you remember something better than emotions or a good night’s sleep
2025-10-07
A good night’s sleep has long been understood to help us consolidate new memories, but we don’t understand how. Associations with negative feelings like fear or stress can improve recall, but intentionally trying to remember can also be effective. But these two mechanisms are very different — one involuntary, one deliberate. Which influences memory most? To investigate, researchers asked participants to remember or forget words, some of which had negative emotional associations. They found that instructions improved recall ...
Solar energy is now the world’s cheapest source of power, a Surrey study finds
2025-10-07
Solar energy is now so cost-effective that, in the sunniest countries, it costs as little as £0.02 to produce one unit of power, making it cheaper than electricity generated from coal, gas or wind, according to a new study from the University of Surrey.
In a study published in Energy and Environment Materials, researchers from Surrey’s Advanced Technology Institute (ATI) argue that solar photovoltaic (PV) technology is now the key driver of the world’s transition to clean, renewable power.
Professor Ravi Silva, co-author of the study and Director of the ATI at the University ...